Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Heideman

Showing results (241-250 of 272) with videos related to

Pageof 28
Sort By:
The Lancet Regional Health. Europe|December 17, 2021
Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: An observational studyFederica Inturrisi, Clare A Aitken, Willem J G Melchers, et al.
Oncotarget|November 7, 2015
Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancerR Jonas A Nilsson, Niki Karachaliou, Jordi Berenguer, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2015
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysisJustine L Kuiper, Lizza E Hendriks, Anthonie J van der Wekken, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2013
EGFR mutation analysis in sputum of lung cancer patients: a multitechnique studyA Jasmijn Hubers, Daniëlle A M Heideman, Yasushi Yatabe, et al.
International Journal of Cancer|September 17, 2015
Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancersE M V de Cuba, P Snaebjornsson, D A M Heideman, et al.
Cellular Oncology (Dordrecht, Netherlands)|April 25, 2012
EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinomaAlexander J J Smits, J Alain Kummer, John W J Hinrichs, et al.
Virchows Archiv : an International Journal of Pathology|December 18, 2012
KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assuranceJ R Dijkstra, D A M Heideman, G A Meijer, et al.
International Journal of Cancer|March 17, 2021
Classification of high-grade cervical intraepithelial neoplasia by p16<sup>ink4a</sup> , Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for managementFrederique J Vink, Stèfanie Dick, Daniëlle A M Heideman, et al.
Molecular Oncology|July 28, 2019
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancerErik J van Helden, Lindsay Angus, C Willemien Menke-van der Houven van Oordt, et al.
Acta Obstetricia Et Gynecologica Scandinavica|September 30, 2022
Adjunctive use of p16 immunohistochemistry for optimizing management of CIN lesions in a high-risk human papillomavirus-positive populationRenée M F Ebisch, L Lucia Rijstenberg, Gilda Ghazi Soltani, et al.
Pageof 28

Showing results (241-250 of 272) with videos related to

Sort By:
Pageof 28
The Lancet Regional Health. Europe|December 17, 2021
Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: An observational studyFederica Inturrisi, Clare A Aitken, Willem J G Melchers, et al.
Oncotarget|November 7, 2015
Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancerR Jonas A Nilsson, Niki Karachaliou, Jordi Berenguer, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2015
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysisJustine L Kuiper, Lizza E Hendriks, Anthonie J van der Wekken, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2013
EGFR mutation analysis in sputum of lung cancer patients: a multitechnique studyA Jasmijn Hubers, Daniëlle A M Heideman, Yasushi Yatabe, et al.
International Journal of Cancer|September 17, 2015
Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancersE M V de Cuba, P Snaebjornsson, D A M Heideman, et al.
Cellular Oncology (Dordrecht, Netherlands)|April 25, 2012
EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinomaAlexander J J Smits, J Alain Kummer, John W J Hinrichs, et al.
Virchows Archiv : an International Journal of Pathology|December 18, 2012
KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assuranceJ R Dijkstra, D A M Heideman, G A Meijer, et al.
International Journal of Cancer|March 17, 2021
Classification of high-grade cervical intraepithelial neoplasia by p16<sup>ink4a</sup> , Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for managementFrederique J Vink, Stèfanie Dick, Daniëlle A M Heideman, et al.
Molecular Oncology|July 28, 2019
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancerErik J van Helden, Lindsay Angus, C Willemien Menke-van der Houven van Oordt, et al.
Acta Obstetricia Et Gynecologica Scandinavica|September 30, 2022
Adjunctive use of p16 immunohistochemistry for optimizing management of CIN lesions in a high-risk human papillomavirus-positive populationRenée M F Ebisch, L Lucia Rijstenberg, Gilda Ghazi Soltani, et al.
Pageof 28